200 related articles for article (PubMed ID: 22375026)
21. Proposed methodology for monitoring antiretroviral drugs price negotiations in Latin America and the Caribbean.
Osorio-de-Castro CG; Crisante M; Miranda ES; Oliveira EA; Oliveira MA
Rev Panam Salud Publica; 2009 Aug; 26(2):137-47. PubMed ID: 19814893
[TBL] [Abstract][Full Text] [Related]
22. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014.
Hamzah NM; Perera PN; Rannan-Eliya RP
BMC Health Serv Res; 2020 Jun; 20(1):509. PubMed ID: 32503539
[TBL] [Abstract][Full Text] [Related]
23. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
Scopel CT; Chaves GC
Cad Saude Publica; 2016 Dec; 32(11):e00113815. PubMed ID: 27925025
[TBL] [Abstract][Full Text] [Related]
24. Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.
Kim SW; Skordis-Worrall J
Health Policy Plan; 2017 May; 32(4):516-526. PubMed ID: 28052986
[TBL] [Abstract][Full Text] [Related]
25. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
26. [Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America].
Oliveira BNL; Oliveira MA
Cad Saude Publica; 2021; 37(10):e00170920. PubMed ID: 34730691
[TBL] [Abstract][Full Text] [Related]
27. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund.
Vasan A; Hoos D; Mukherjee JS; Farmer PE; Rosenfield AG; Perriëns JH
Bull World Health Organ; 2006 May; 84(5):393-8. PubMed ID: 16710550
[TBL] [Abstract][Full Text] [Related]
28. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
29. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.
Ford N; Wilson D; Costa Chaves G; Lotrowska M; Kijtiwatchakul K
AIDS; 2007 Jul; 21 Suppl 4():S21-9. PubMed ID: 17620749
[TBL] [Abstract][Full Text] [Related]
30. Drugs for STD management in developing countries: choice, procurement, cost, and financing.
Van der Veen F; Fransen L
Sex Transm Infect; 1998 Jun; 74 Suppl 1():S166-74. PubMed ID: 10023369
[TBL] [Abstract][Full Text] [Related]
31. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
32. Drug makers to cut prices for developing countries.
AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
[TBL] [Abstract][Full Text] [Related]
33. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
[TBL] [Abstract][Full Text] [Related]
34. Negotiation Strategies for Antiretroviral Drug Purchasers in the United States.
Linnemayr S; Ryan GW; Karir V; Liu J; Palar K
Rand Health Q; 2012; 2(3):7. PubMed ID: 28083266
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi.
Schouten EJ; Jahn A; Ben-Smith A; Makombe SD; Harries AD; Aboagye-Nyame F; Chimbwandira F
J Int AIDS Soc; 2011 Jul; 14 Suppl 1():S4. PubMed ID: 21967844
[TBL] [Abstract][Full Text] [Related]
36. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Global Health; 2017 Aug; 13(1):53. PubMed ID: 28764738
[TBL] [Abstract][Full Text] [Related]
37. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
38. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
[TBL] [Abstract][Full Text] [Related]
39. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
40. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
